TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21933851
Drug: Chemotherapy-only for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-only for patients with 11q23 aberrations (n = 49)
Study: 9129064
Drug: zidovudine monotherapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine monotherapy
Study: 7477798
Drug: Etomidate (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.30 mg/kg IV induction, 0.02 mg/kg/min continuous infusion for 24-72 hours)
Study: 7477798
Drug: Pentobarbital (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (not detailed in dosage or duration)
Study: 2154925
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated oral rhesus Rotavirus candidate vaccine (strain MMU 18006 [lot RRV‐1])
Study: 22848006
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (1000 mg testosterone undecanoate, n=33)
Study: 17668541
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg/g ointment
Study: 15018018
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg/g ointment
Study: 15957724
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low dose oral midazolam (0.25 mg/kg) and low dose oral ketamine (3 mg/kg)
Study: 12024143
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MRCP and EUS
Study: 8580228
Drug: Phototherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapy treatment for 1 week
Study: 1265780
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 1g Podophyllum/day after irradiation (128 patients)
Study: 25910800
Drug: Known AF
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Known AF without OAC treatment
Study: 17107615
Drug: Antithrombin therapy
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin therapy
Study: 1854075
Drug: Inhalation rewarming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation rewarming
Study: 1854075
Drug: Inhalation rewarming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation rewarming and peripheral rewarming evaluated separately or in combination
Study: 6889154
Drug: sulfisoxazole at
Normalized name: Sulfisoxazole
DrugBank: Sulfisoxazole (DB00263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfisoxazole at 500 mg twice a day
Study: 6889154
Drug: both pneumococcal
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both pneumococcal vaccine and 500 mg sulfisoxazole twice daily
Study: 6889154
Drug: no routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: no routine medication
Study: 6889154
Drug: antihistamines whenever
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: antihistamines whenever nasally congested
Study: 17765616
Drug: Metoprolol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (n = 60, mean daily dose of 93 +/- 11 mg)
Study: 15124719
Drug: Tongue‐muscle training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue‐muscle training (20 minutes twice a day for 8 weeks)
Study: 2596736
Drug: IV aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV aminophylline (6 mg/kg over fifteen minutes)
Study: 28328148
Drug: XR-NTX (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX (extended-release naltrexone)
Study: 19692680
Drug: Carboplatin-paclitaxel (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin-paclitaxel (carboplatin dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute plus paclitaxel 200 mg per square meter of body-surface area)
Study: 16467543
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (160 mg twice a day)
Study: 11130223
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided by clinical pharmacists
Study: 25704652
Drug: Glimepiride (GL)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride (GL) 3mg/d + ketotifen 1mg twice daily
Study: 25704652
Drug: Glimepiride (GL)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride (GL) 3mg/d + ketotifen 1mg once daily
Study: 23143410
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (20 cc)
Study: 23143410
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 cc 5% dextrose solution)
Study: 9892449
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and medication clinic visits
Study: 8670319
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with growth hormone
Study: 8670319
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with growth hormone and glucagon
Study: 2070058
Drug: Natural interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural interferon-alpha (nIFN-alpha) therapy at doses of 3 million IU, three times a week
Study: 2070058
Drug: Recombinant interferon-alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon-alpha-2a (rIFN-alpha-2a) therapy
Study: 24836312
Drug: Pirfenidone (2403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (2403 mg per day)
Study: 18269638
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart (BIAsp) thrice-daily regimen
Study: 18269638
Drug: Biphasic human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic human insulin (BHI) 30 group
Study: 10484801
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg)
Study: 1448739
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (750 milligrams) prophylactic cefamandole delivered directly into the operative wound with local anesthesia
Study: 8419612
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone therapy
Study: 26527204
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances (OAs)
Study: 23867247
Drug: Xifeng Dingchan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xifeng Dingchan Pill (XFDCP) with Madopar for early-stage PD (n = 80)
Study: 23867247
Drug: Xifeng Dingchan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xifeng Dingchan Pill (XFDCP) combined with Madopar and Piribedil for middle-stage PD (n = 80)
Study: 9184388
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant hirudin (HBW 023)
Study: 1530173
Drug: 0.25% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% ropivacaine (112.5 mg)
Study: 1530173
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (112.5 mg)
Study: 17977950
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment for 16 weeks
Study: 20921315
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg loading dose followed by 50 mg every 12 hours)
Study: 12049012
Drug: Conventional absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional absorbable subcutaneous Polyglactin 910 (VICRYL, ETHICON) and non absorbable cutaneous Monofilament Nylon (ETHILON, ETHICON) stitches
Study: 12049012
Drug: Running subcutaneous
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Running subcutaneous and intradermic irradiated Polyglactin 910/370 (VICRYL‐Rapide, ETHICON) sutures
Study: 7945744
Drug: Apomorphine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.01 mg/kg SC)
Study: 7945744
Drug: MK-212 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-212 (20 mg PO)
Study: 3111514
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg orally four times daily for 4 days
Study: 3111514
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg orally twice daily for 4 days
Study: 3111514
Drug: Glibenclamide administered
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide administered alone
Study: 15705011
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75 to 225 mg/day)
Study: 9424681
Drug: d‐tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine 0.05 mg/kg
Study: 30445999
Drug: Letrozole (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (oral fertility medication)
Study: 27902622
Drug: Penetration acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penetration acupuncture treatment on head combined with conventional treatment (treatment group [TG])
Study: 27902622
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only (control group [CG])
Study: 16595599
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g twice daily)
Study: 16154855
Drug: Daily 3-hour
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily 3-hour fast infusions of arsenic trioxide (As2O3)
Study: 16154855
Drug: Daily slow,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily slow, continuous infusions of arsenic trioxide (As2O3)
Study: 9170398
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium antagonist
Study: 31356878
Drug: ASP7962 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP7962 (100 mg BID)
Study: 12017396
Drug: naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500 mg BID)
Study: 30146144
Drug: Structured Cognitive-Behavioral
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Cognitive-Behavioral Therapy (CBT)
Study: 30146144
Drug: Less-Structured Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-Structured Cognitive-Behavioral Therapy (CBT)
Study: 29168127
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg DAA-I
Study: 24045586
Drug: Meclizine 12.5
Normalized name: meclizine 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine 12.5 mg
Study: 24045586
Drug: Meclizine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclizine (both doses)
Study: 7768259
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan
Study: 29402332
Drug: Co-trimoxazole 480
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 480 mg (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Study: 29402332
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Study: 23062189
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg/day increasing to 300 or 450 mg/day)
Study: 17953762
Drug: Clindamycin cream
Normalized name: clindamycin Vaginal Cream
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin cream treatment
Study: 16087950
Drug: CAF-Z (CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF-Z (CAF followed by 5 years of monthly goserelin)
Study: 7624530
Drug: Oral temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral temperature measurement
Study: 909754
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of metenolone during MOPP chemotherapy
Study: 909754
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy without androgenotherapy (implied control)
Study: 31793398
Drug: Tiotropium-Olodaterol combination
Normalized name: olodaterol / tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium-Olodaterol combination
Study: 31161202
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (intervention relaxation group)
Study: 27646197
Drug: L-DOPA and
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA and Placebo
Study: 19407262
Drug: Direct switch
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct switch from subcutaneous rHuEPO to intravenous darbepoetin (group 1)
Study: 19407262
Drug: Indirect switch
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect switch from subcutaneous rHuEPO to intravenous darbepoetin after 2 months of subcutaneous darbepoetin (group 2)
Study: 19407262
Drug: Intravenous rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rHuEPO switched to intravenous darbepoetin (control group)
Study: 15459145
Drug: Sequential antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential antibiotic treatment
Study: 2869574
Drug: prenalterol (beta‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: prenalterol (beta‐1 agonist)
Study: 30527839
Drug: Vilaprisan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 0.5 mg
Study: 30527839
Drug: Vilaprisan 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 1.0 mg
Study: 30527839
Drug: Vilaprisan 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 2.0 mg
Study: 30527839
Drug: Vilaprisan 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 4.0 mg
Study: 30527839
Drug: Vilaprisan (≥1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (≥1.0 mg)
Study: 26848792
Drug: 26-week dose
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26-week dose reduction group
Study: 26848792
Drug: No-dose-reduction group
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-dose-reduction group
Study: 19020157
Drug: Tapentadol HCl
Normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol HCl 50 mg
Study: 19020157
Drug: Tapentadol HCl
Normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol HCl 100 mg
Study: 19020157
Drug: Tapentadol HCl
Normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol HCl 200 mg
Study: 19020157
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 60 mg
Study: 19020157
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of tapentadol HCl
Study: 16635169
Drug: 30% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% glucose solution
Study: 8781610
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of cyclosporine (CsA)
Study: 8781610
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporine (CsA)
Study: 20427729
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplements (1000 IU of either D(2) or D(3))
Study: 16248239
Drug: Modified huanglian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified huanglian wendan decoction (MHWD) plus Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Study: 16248239
Drug: Xinkang tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Study: 3421264
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antihypertensive therapy)
Study: 26434885
Drug: Intravenous gemcitabine/cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gemcitabine/cisplatin regimen plus daily oral metformin 500 mg (arm A)
Study: 26434885
Drug: Intravenous gemcitabine/cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gemcitabine/cisplatin regimen alone (arm B)
Study: 768911
Drug: Acebutolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (mean dosage 10 mg/kg, maximum 22 mg/kg)
Study: 31883082
Drug: Blonanserin transdermal
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin transdermal patches (40-80 mg/day for 52 weeks)
Study: 23320780
Drug: Cemented bipolar
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cemented bipolar implant (n=133)
Study: 12536495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LMWH treatment)
Study: 12928047
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serum markers including interleukin‐6 (IL‐6) receptor, protein alpha1 fraction, cysteine, and cholesterol concentrations
Study: 9087161
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal aerosol (once daily for 6 weeks)
Study: 22982184
Drug: Teduglutide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide (0.05 mg/kg/d)
Study: 10703128
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug delivery system
Study: 6377997
Drug: Daily streptomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months
Study: 6377997
Drug: Daily streptomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 3 months
Study: 6789733
Drug: Selective chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective chemotherapy (treatment started only after active disease confirmation)
Study: 31075954
Drug: Phytochemicals (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytochemicals (e.g., agaricus, curcumin, Neovastat)
Study: 15331972
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (general)
Study: 25775225
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient group treatment (both MI groups)
Study: 17851566
Drug: Warfarin by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin by a validated algorithm
Study: 12794711
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy with reverse transcriptase inhibitors
Study: 10575565
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b combined with ribavirin (1000 mg/day)
Study: 2066757
Drug: Immediate adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate adjuvant chemotherapy
Study: 31170954
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy
Study: 21302033
Drug: Zolpidem alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem alone (5 mg)
Study: 21985609
Drug: Zolpidem after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem after pretreatment with fluvoxamine (5 mg zolpidem + 100 mg fluvoxamine)
Study: 20807867
Drug: Topical arnica
Normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical arnica cream
Study: 15267190
Drug: ROM (rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROM (rifampicin 600 mg + ofloxacin 400 mg + minocycline 100 mg)
Study: 10586091
Drug: IL-2 in
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 in association with antiretroviral therapy (ART)
Study: 8762699
Drug: sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol (320 mg po/d for 4 weeks)
Study: 8762699
Drug: sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol (320 mg po/d for 4 weeks) in patients with Chagas' disease
Study: 6682669
Drug: Doxycycline monotherapy
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline monotherapy
Study: 6682669
Drug: Isoconazole nitrate
Normalized name: isoconazole nitrate
DrugBank: Isoconazole (DB08943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoconazole nitrate (300 mg/day and 600 mg/day for 14 days)
Study: 31318821
Drug: Cognitive-emotional intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-emotional intervention (5 sessions, 60 to 90 minutes each, held twice a week)
Study: 20658442
Drug: L-carnitine 1
Normalized name: L-Carnitine 1,000mg Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 1 g iv after each HD session for 12 weeks
Study: 18076732
Drug: Oil-assisted technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-assisted technique (corn seed oil injection) - Group B
Study: 17697220
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam (0.2 mg x kg(‐1))